表紙
年間契約型情報サービス

バイオシミラーインデックス:世界のバイオシミラー開発状況追跡調査

Biosimilar Index: Tracking the Biosimilar Development Landscape

発行 FirstWord 商品コード 298599
出版日 年間契約型情報サービス ページ情報 英文 Database + 135 Slides
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
バイオシミラーインデックス:世界のバイオシミラー開発状況追跡調査 Biosimilar Index: Tracking the Biosimilar Development Landscape
出版日: 年間契約型情報サービス ページ情報: 英文 Database + 135 Slides
担当者のコメント
データは週に2-3回の頻度で更新されます。データベースはMS-Excelとなりますので、最新情報が反映されたファイルをその都度ダウンロード頂くものです。パワーポイントのプレゼンテーションファイルは四半期に1度の更新となります。ご購入から1年間ダウンロードが可能です。
概要

当レポートでは、世界における主要バイオシミラーの開発状況に関するアップデートおよび極めて詳細な分析を提供しており、概略以下の構成でお届けします。

バイオシミラーインデックス:パイプラインデータベース

データベースの主な内容

  • 参照製品のブランド名
  • 適応症および参照製品の売上報告
  • 発案企業
  • バイオシミラー開発企業
  • 開発企業の本部の所在地
  • 治療クラス
  • 主要指標
  • アプリケーション形態・管理ルート
  • 治験状況
  • 世界のマーケティング状況
  • マーケティング合意・ライセンシング機会

バイオシミラーインデックス:情勢のレビュー

  • 以下を含む最も重要な構造化データ
    • 参照製品の売上データ
    • 現在・将来の市場における画期的出来事
    • 各主要製品のシングルビュー分析
    • 治験活動・開発段階のフローチャート
  • 本サービスは、治験登録、企業コミュニケーション、会議の議事録、ブローカー分析およびソーシャルメディアなど、幅広い信頼性の高い情報ソースを引用
  • 知識の豊富な専門家による強力な解説と分析
  • Microsoft PowerPoint形式で提示
目次

A new force in biosimilar and NCB drug and market tracking

FirstView's Biosimilar Index is a new, comprehensive drug intelligence service which provides a robust, dynamically updated and highly-detailed insight into the status of leading biosimilar and NCB assets in development worldwide. Exhaustively referenced and sourced, it is one of the most comprehensive analyses of its type providing both on-going tracking of development and interpretation of the commercial and clinical significance.

Two class beating services in one subscription!

Biosimilar Index: Pipeline Database

The Biosimilars Index: Pipeline Database is checked daily. When a significant event happens, the database is updated, thereby ensuring you're up to date with current market dynamics. The database is provided as a dynamic MS Excel™ file with complete data and filter analysis tools included.

Available 24/7 through a secure password protected site, there are no limits on how frequently you can download the XLS file. Having access to the database enables you to see the whole biosimilar and NCB landscape across multiple classes and geographies

Essential details covered in the database include:

  • Brand name(s) of reference products
  • Indications and reported sales for the reference product
  • Originator company
  • Biosimilars development company
  • HQ location of development company
  • Therapy class
  • Key indication(s)
  • Mode of application and route of administration
  • Clinical trials status
  • Global marketing status
  • Marketing agreements and licensing opportunities

Powerful data with intuitive analysis tools

With Biosimilars Index: Pipeline Database at hand, you can effortlessly compare and contrast biosimilars in development by country, originator company, stage of development, condition and therapeutic area. The data is provided in MS Excel™ and comes with filters and search built in. The data can easily be exported to your own analytics package or data visualisation platform.

Biosimilar Index: Landscape Review

What's hot and what's not? The biosimilars sector is constantly evolving. Important research progress, commercial deals and product launches are regularly announced. The Biosimilar Index: Landscape Review strips away market rumour and speculation to tell you exactly what has happened and why it is important.

Published quarterly, the Review is based on the daily-updated research in the Biosimilar Index: Pipeline Database, enhanced by critical insights and understanding from biosimilars experts.

The benefits and features of the Biosimilar Index: Landscape Review...

  • Includes essential structured data including
    • Sales data for reference products
    • Current and future market milestones
    • Individual single view analysis for leading products
    • Clinical trial activities and flow charts of development phase.
  • The service draws on a wide-range of reliable information sources such as clinical trial registries, company communications, conference proceedings, broker analysis and social media.
  • Includes powerful interpretation and analysis by knowledgeable experts to ensure that developments are scrutinised and the implications highlighted.
  • Presented in MS PowerPoint™ to bring clarity to the extensive charting and tables provided which can be incorporated into your own presentations

Key benefits and features:

With Biosimilar Index you can...

  • Understand the biosimilar and NCB development landscape through comprehensive coverage of the pipelines of all major biosimilar developers worldwide
  • Drill down to discover the levels of potential biosimilar competition by therapy area, drug class status and geography
  • Establish the level of biosimilar competition for leading biologic brands
  • Learn which biosimilar developers are potential future competitors or collaborators
  • Identify the biosimilar and NCB portfolios of over 130 companies and discover the leaders in product development for which products/therapy areas
  • Know where the development hotspots are and what research is taking place.

The Biosimilar Index is feature rich...

  • Includes both structured data and commercial interpretation
  • The Biosimilar Index: Pipeline Database covers all significant biosimilar products and is updated daily. Available 24/7 in MS Excel™ with unlimited downloads which can be incorporated into your own analytics package or visualisation software
  • The Biosimilar Index: Landscape Review provides and insightful quarterly analysis which identifies the developments that are really important
  • Biosimilar Index is Informed by a wide-range of respected sources with expert internal and external inputs and oversight

A service for the whole industry

Whether you work in big pharma, a biosimilars development company, a clinical service organisation, a regulatory body or in commercial investment and finance, the Biosimilar Index provides a clear window on the world of biosimilar drugs and their developers.

With the Biosimilar Index you are always in the know!

Table of Contents

Introduction

Executive summary

Reference medicinal product data

Market milestones; Q1 2013 - Q1 2014

Potential future milestones; Q2 2014 - Q4 2014

Biosimilar programme analysis

  • Pipeline summary by molecule
  • Clinical trials by molecule

Appendix

  • Data sources
  • Definitions and terminology
  • Disclaimer

[139 slides]

List of Companies

  • AbbVie
  • Idec Pharmaceuticals
  • Sanofi
  • Genentech
  • Centocor
  • Immunex
  • Amgen Genentech
  • Kirin Holdings
  • Novo Nordisk
  • Biogen Idec
  • Eli Lilly
  • Sanofi
  • Novo Nordisk
Back to Top